<?xml version="1.0" encoding="UTF-8"?>
<p>In STZ-induced diabetic mice, MCPIIaC strengthens the antioxidant enzyme defense system and weakens peroxidation of lipids in a dose-related manner, which indicates that the antidiabetic effect of MCPIIaC may be relevant to its antiglycation ability [
 <xref rid="B70" ref-type="bibr">70</xref>]. Selenylated MCP reinforces its hypoglycemic activity by increasing antioxidant enzyme activity [
 <xref rid="B71" ref-type="bibr">71</xref>]. MCP orally restores TAOC by improving the level of SOD and declining the level of MDA [
 <xref rid="B43" ref-type="bibr">43</xref>]. It is also shown that MCP treatment in diabetic rats can significantly increase GSH, SOD, and catalase (CAT) levels via heme oxygenase-1 (HO-1)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, while it can decrease MDA in diabetic kidneys [
 <xref rid="B81" ref-type="bibr">81</xref>]. In addition, in high-fat-induced obese rats, allosteric MCP through 
 <italic>Momordica charantia</italic> fermentation decreases the lipid and oxidative stress level, resulting in the remarkable reduction of insulin resistance [
 <xref rid="B82" ref-type="bibr">82</xref>].
</p>
